A5058192089- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Breast Lesions and Carcinomas
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
- Estrogen and related hormone effects
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- Cancer Diagnosis and Treatment
- Metastasis and carcinoma case studies
- Cancer Genomics and Diagnostics
- Salivary Gland Tumors Diagnosis and Treatment
- Cancer, Stress, Anesthesia, and Immune Response
- Prostate Cancer Treatment and Research
- Medical Imaging Techniques and Applications
- PARP inhibition in cancer therapy
- CAR-T cell therapy research
- BRCA gene mutations in cancer
- Cancer Risks and Factors
- Gastrointestinal disorders and treatments
- Histone Deacetylase Inhibitors Research
- Inflammatory Myopathies and Dermatomyositis
Kumamoto City Hospital
2013-2023
Chemotherapy Foundation
2016
The Cancer Institute Hospital
2010
Kumamotorosaibyoin
2001
Tumors can recur years after treatment, and breast cancer is especially noted for long periods of dormancy. The status the during this period poorly understood. As a model to study mechanisms dormancy, we used murine D2.0R mammary carcinoma cells, which are metastatic but form occasional metastases in liver other organs latency. Highly D2A1 cells provided positive, control. Our goals were learn how cell lines differ survival kinetics secondary site seek evidence source In spontaneous...
The choice of adjuvant systemic therapy is based on targeted in line with the St. Gallen Consensus meeting. In addition to traditional parameters, panel recommended use proliferation markers and multigene assays. purpose present study was evaluate clinical significance proliferative activity using Ki-67 index as a prognostic marker predictor recurrence time breast cancer patients. measured 3,652 cases primary from 1987 2009. Out these patients, 2,638 were evaluated simultaneously for...
This study included patients with primary triple-negative breast cancer (TNBC) who underwent resection without neoadjuvant chemotherapy between January 2004 and December 2014. Among the 248 TNBCs studied, programmed cell death ligand-1 (PD-L1) expression was detected in 103 (41.5%) tumors, high levels of tumor-infiltrating lymphocytes (TILs) were present 118 (47.6%) tumors. PD-L1 correlated TILs, but not a prognostic factor. Patients TILs-high tumors had better overall survival than those...
In breast cancer, ER/PgR, HER2, and Ki-67 are important biological markers for predicting prognosis making effective treatment decisions. addition, changes in due to relapse also clinically experienced; however, the frequency clinical significance still not fully understood. Thus, their correlations with were investigated. Out of patients from 1997 March 2011, there 97 consecutive whom lesion was resected evaluated by immunostaining. The biopsy sites chest wall, lymph node, ipsilateral tumor...
The Ki-67 index is an important biomarker for indicating the proliferation of cancer cells and considered to be effective prognostic factor breast cancer. However, a standard cut-off point has not yet been established. Therefore, aim this retrospective study was determine optimal in order establish it as more accurate factor. Immunohistochemical analysis performed on 4329 patients with primary from August 1987 March 2012. Out sample, there were 3186 consecutive cases September 1997...
The Ki-67 index value is a prognostic factor in primary breast cancer and proliferation marker that also distinguishes between luminal type A B cancer. Moreover, change values due to treatment recurrence considered be important treating In this study, we investigated whether the baseline tumor useful as following disease recurrence. Immunohistochemical analysis of was performed on 4,701 patients with from 1987 until March, 2013. Among these patients, there were 666 consecutive cases...
Insufficient attention for the Ki-67 immunohistochemistry has been given to importance of tissue handling surgical breast cancer specimens. We sought investigate effect fixation status on Ki-67.
The value of assessing tumor infiltrating lymphocytes (TILs) in estrogen receptor (ER) positive/human epidermal growth factor type 2 (HER2) negative breast cancer has yet to be determined. In the present study, a total 184 cases with early distant recurrence detected within 5 years following primary operation, 134 late diagnosed or longer and 321 controls without for >10 starting initial treatment ER‑positive/HER2 cancer, registered 9 institutions, were analyzed. distributions TILs their...
The significance of the expression aldehyde dehydrogenase 1 (ALDH1), a cancer stem cell marker, for predicting recurrence estrogen receptor (ER)-positive/human epidermal growth factor type 2 (HER2)-negative breast is still poorly understood. value ALDH1 in time remains unknown. In total, 184 patients with early distant recurrence, 134 late and 321 control without more than 10 years after starting initial treatment ER-positive/HER2-negative cancer, registered 9 institutions, were analyzed. We...
Tumor-infiltrating lymphocytes in the tumor microenvironment are important treatment of triple-negative breast cancer (TNBC). Cytotoxic T cells produce cytokines and cytotoxic factors, such as perforin granzyme, which induce apoptosis by damaging target cells. To identify biomarkers these cells, we investigated granzyme B (GZMB) a biomarker response prognosis 230 patients with primary TNBC who underwent surgery without preoperative chemotherapy between January 2004 December 2014. Programmed...
Gene profiling has identified at least 4 breast cancer subtypes, including Luminal A, B, HER2-enriched and basal-like, immunohistochemistry is used as a guide to determine these subtypes. In the present study, patients with ER-positive, HER2-negative negative nodes were classified into groups according PgR Ki-67 status retrospectively examined. The analysis was based on clinicopathological findings, includes recurrence score (RS) disease-free survival (DFS) rates. Patients invasive (n=1866)...
Triple-negative breast cancer (TNBC) is a heterogeneous tumor that encompasses many different subclasses of the disease. In this study, we assessed BRCAness, defined as shared characteristics between sporadic and BRCA1-mutated tumors, in large cohort TNBC cases.The BRCAness 262 patients with primary TNBCs resected January 2004 December 2014 was determined through isolation DNA from tissue. Classification performed using multiple ligation-dependent probe amplification (MLPA). The subtypes...
T-box transcription factor 21 (T-bet), which is the master regulator of effector T-cell activation, derived by stimulation receptors. In this study, we focused on T-bet and examined function activated T cells.This study included 242 patients with primary triple-negative breast cancer (TNBC) who underwent resection without neoadjuvant chemotherapy between January 2004 December 2014. The immunohistochemistry scoring for CD8 expression tumor-infiltrating lymphocytes (TILs) was defined as ≥ 30...
Abstract Background It is important to identify biomarkers for triple-negative breast cancers (TNBCs). Recently, pembrolizumab, an immune checkpoint inhibitor (ICI) programmed cell death 1 (PD-1), was approved as a treatment strategy unresectable or metastatic tumor with high-frequency microsatellite instability (MSI-H) mismatch repair deficiency, such malignant melanoma, non-small lung cancer, renal cancer and urothelial cancer. In addition, results from clinical trials suggested that ICI...
Triple negative breast cancer (TNBC) is a subtype of which lacks hormone receptor (HR) expression and HER2 gene amplification the most aggressive subtype, with heterogeneous genetic profile. The aim this retrospective study was to evaluate clinical significance menopausal status in cases TNBC. Primary patients who underwent curative surgery were enrolled study. A total 5153 invasive Stage I-III analyzed. distribution according subtypes investigated clinicopathological characteristics...
Lymphovascular invasion (LVI) is associated with a poor outcome in breast cancer. The purpose of the present study was to evaluate clinical significance LVI primary cancer and investigate disease‑free survival as prognostic marker according subtypes. This examined 4,652 consecutive cases invasive excluding patients non‑invasive cancer, stage IV those who underwent neo‑adjuvant therapy from February 2002 2021. clinicopathological characteristics prognosis LVI‑positive ‑negative tumors were...
Analysis of sentinel lymph nodes (SLNs) by means One-Step Nucleic Acid Amplification (OSNA) is gaining widespread use as a quick and accurate method. This assay detects the expression level cytokeratin 19 (CK19) which present in some but not all breast tumors. In this study, clinical significance negative CK19 was investigated 219 cases primary cancer. 179 patients with clinically nodes, OSNA imprint smear cytology SLN were performed simultaneously. The revealed node-positive rate 24.6%....
Estrogen receptor (ER) and progesterone (PgR) status are predictive factors for the clinical pathological response to neoadjuvant chemotherapy operable breast cancer. However, it remains unclear as how proportion of ER-positive or PgR-positive tumor cells affects chemotherapy. We examined correlation with human epidermal growth factor 2 (HER2)-negative From April 2002 October 2010, 103 patients received containing epirubicin taxane in our clinic. A was observed 86 (83%) patients, a complete...
<b><i>Objective:</i></b> In this case-control study, we investigated the most suitable cell counting area and optimal cutoff point of Ki-67 index. <b><i>Methods:</i></b> Thirty recurrent cases were selected among hormone receptor (HR)-positive/HER2-negative breast cancer patients. As controls, 90 nonrecurrent randomly by allotting 3 controls to each case based on following criteria: age, nodal status, tumor size, adjuvant endocrine therapy...